&nbsp;

brad-campbell.jpg

Jan 2023

Drug

binimetinib

Other Name(s): Mektovi®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jul 2023

Document

Breast Cancer Patient Information Sheet - Other Languages.zip

May 2023

Regimen

BEVA+PEMB(MNT)

Cancer Type:

Gynecologic,

Cervix

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Drugs Used:

pembrolizumab,

bevacizumab

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

BEACOPDAC(ESC)

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

BEACOPDAC-14

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

TRIFTIPI+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

Exceptional Access Program

trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer

trifluridine / tipiracil,

Drugs Used:

bevacizumab

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

BORTDEXALENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT

ODB Limited Use

lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2023

Regimen

TISL(MNT)

Cancer Type:

Head and Neck,

Nasopharynx

Intent: Palliative

Drugs Used:

tislelizumab (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Apr 2024

Document

basic-template

May 2024

Document

test.png

Jun 2024

Document